Impact of paliperidone palmitate one-month formulation on relapse prevention in patients with schizophrenia: A post-hoc analysis of a one-year, open-label study stratified by medication adherence

Journal of Psychopharmacology
Tianmei SiYu Feng

Abstract

Limited data are available to help identify patients with schizophrenia who are most likely to benefit from long-acting injectable antipsychotics. To investigate the efficacy of long-acting injectable antipsychotic paliperidone palmitate one-month formulation for preventing relapses, factors influencing time to first relapse, and the effect of different antipsychotic adherence levels on time to first relapse in Chinese patients with schizophrenia. This was a post-hoc analysis from an open-label, single-arm study of stable patients (Positive and Negative Syndrome Scale total score <70; n=367) receiving paliperidone palmitate one-month formulation at the end of an acute 13-week treatment phase, who entered a naturalistic one-year follow-up period, either continuing with flexibly dosed paliperidone palmitate one-month formulation (75-150 mg eq.) or switching to another antipsychotic(s). There were 362/367 patients (age=31.4±10.75 years) included in the analysis of time to first relapse (primary outcome) and 327/362 patients (39/327, poor antipsychotic adherence (<80%)) willing to receive antipsychotics were included in the exposure/adherence analysis. Overall, 84.6% (95% confidence interval=79.2-88.7) patients remained relapse-fre...Continue Reading

References

Apr 16, 1998·The British Journal of Psychiatry : the Journal of Mental Science·V PatelA Mann
Apr 2, 2004·The British Journal of Psychiatry : the Journal of Mental Science·Stephen AlmondTraolach Brugha
May 3, 2006·The Journal of Clinical Psychiatry·Haya Ascher-SvanumJeff W Swanson
Oct 19, 2006·Journal of Psychopharmacology·Henry A Nasrallah, Rob Lasser
Dec 7, 2007·The Journal of Clinical Psychiatry·Noel C Gardner
May 28, 2010·The British Journal of Psychiatry. Supplement·John M Kane, Carlos Garcia-Ribera
Jul 1, 2010·Expert Opinion on Pharmacotherapy·Ofer AgidGary Remington
Nov 26, 2010·Progress in Neuro-psychopharmacology & Biological Psychiatry·Gahan PandinaGeorge Simpson
Feb 15, 2011·Progress in Neuro-psychopharmacology & Biological Psychiatry·Huafang LiNiufan Gu
Jun 23, 2012·Journal of Psychiatric Research·Olalla CaseiroBenedicto Crespo-Facorro
Aug 16, 2013·Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie·Ashok MallaMarc-André Roy
Oct 8, 2013·World Psychiatry : Official Journal of the World Psychiatric Association (WPA)·John M KaneChristoph U Correll
May 23, 2014·JAMA : the Journal of the American Medical Association·Joseph P McEvoyT Scott Stroup
Dec 3, 2014·European Psychiatry : the Journal of the Association of European Psychiatrists·S HeresR Vauth
Mar 21, 2015·Neuropsychiatric Disease and Treatment·Fan ZhangSteve Ascher
Oct 13, 2016·The Journal of Clinical Psychiatry·Christoph U CorrellJohn M Kane

❮ Previous
Next ❯

Clinical Trials Mentioned

NCT01685931

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here